During the last three months, 4 analysts shared their evaluations of Rhythm Pharmaceuticals (NASDAQ:RYTM), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Analysts have recently evaluated Rhythm Pharmaceuticals and provided 12-month price targets. The average target is $59.5, accompanied by a high estimate of $64.00 and a low estimate of $55.00. Surpassing the previous average price target of $50.50, the current average has in…